In the realm of medical companies, Tempus AI and PubMatic have emerged as key players, but which one holds greater investment potential? To determine this, we will compare the two companies based on various factors such as earnings, valuation, dividends, risk, profitability, analyst recommendations, and institutional ownership.
When it comes to institutional and insider ownership, PubMatic takes the lead. Approximately 64.3% of PubMatic shares are held by institutional investors, indicating a strong belief in the company’s long-term growth prospects. In contrast, only 2.9% of PubMatic shares are held by insiders.
Moving on to valuation and earnings, a comparison of revenue, earnings per share (EPS), and valuation reveals that Tempus AI and PubMatic differ in their financial performance.
Analyst ratings also play a crucial role in assessing investment potential. According to MarketBeat.com, Tempus AI currently has a consensus price target of $45.56, suggesting a potential downside of 7.46%. On the other hand, PubMatic has a consensus price target of $21.00, indicating a potential upside of 43.74%. Analysts seem to favor PubMatic, considering its higher possible upside.
Examining profitability, PubMatic outperforms Tempus AI on several fronts. PubMatic boasts higher net margins, return on equity, and return on assets compared to Tempus AI.
In summary, PubMatic emerges as the stronger contender, surpassing Tempus AI on six out of the ten factors analyzed. Tempus AI, based in Chicago, focuses on advancing precision medicine through the practical application of artificial intelligence in healthcare. Meanwhile, PubMatic, headquartered in Redwood City, California, provides a cloud infrastructure platform for real-time programmatic advertising transactions.